Spotlight
Topic
Brand Insights
Subscribe
- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Pfizer Depression Candidate Fails in Phase 3 Study
January 04, 2016.
FDA News reports that Pfizer’s Phase 3 study of Pristiq, a treatment for major depressive disorder, failed to meet its primary objective of superiority versus placebo in a study evaluating the drug for children between the ages of 7 and 17.
This is the second Phase 3 study for pediatric patients receiving Pristiq that did not demonstrate superior efficacy versus placebo, according to FDA News.
Pristiq was approved in 2008 for the treatment of major depressive disorder in adults.
Recent Videos
Related Content
